Merck reports quarterly results that beat expectations and raises its profit forecast, citing strong momentum for Keytruda in an injectable form. The company’s adjusted profit outlook increases, reflecting higher expected performance from its cancer immunotherapy portfolio.
Across the coverage, both outlets focus on Keytruda’s newer presentation as the key driver. Quartz highlights the injection-related sales figures and specifies the range shift in its adjusted profit forecast. CNBC emphasizes that the injectable form shows strength and frames the update around how the product continues to outperform expectations. While the outlets differ in how much numerical detail they provide, they agree on the core storyline: better-than-expected results tied to Keytruda’s injectable sales and a higher profit outlook.
